EGFR and neoplasm: In patients experiencing an oligoprogression after a durable response to EGFR-TKI, the strategy to maintain the inhibition of EGFR inhibitor-sensitive clones, to avoid the potential subsequent rebound tumor flare and symptomatic progression, is frequently used in clinical practice.